临床试验注册数,中国超过印度

August 28, 2007, 8:54 am
China Overtakes India in Clinical-Trial Registry
中国注册的临床试验数量超越印度
Posted by Jacob Goldstein
Jacob Goldstein发布

More clinical trials are now under way in China than in India, according to a U.S.-based registry that lists clinical trials from around the world, the Financial Times reports.
财经时报报道：根据在美国已注册的全球临床试验数据可知，现在在中国比在印度有更多的临床试验在进行中。

China now has 274 clinical trials in progress, compared with 260 in India, according to the database, clinicaltrials.gov. The database also says China has 510 completed or ongoing trials compared with 471 in India. Until recently, India showed higher numbers on both measures, according to the FT.
参照clinicaltrials.gov的数据库，对比与印度的260个临床试验，中国现在有274个在进行中。该数据库同时显示在中国有510个已完成和正在进行的临床试验，而印度只有471个。按照财经时报的说法，直到最近印度才在两个方面都有所增长。

Those numbers represent a tiny percentage of the more than 40,000 trials listed on clinicaltrials.gov. And there may be trials under way in both countries that are not listed in the database. Still, the finding is interesting because of the increasing attention international drug makers — who register many of their trials on clinicaltrials.gov — are paying to both research and sales in the developing world.
这个数字仅是clinicaltrials.gov上列出的40,000个实验中的一小部分。而且可能有些在两个国家都在进行的试验并未列入这个数据库。但是，因为跨国药厂——在clinicaltrials.gov上注册了他们大部分试验——正在对发展中国家的研究及销售越来越感兴趣这个现象是个有趣的发现。

Novartis recently lost a patent case in India and said it had changed its plans to invest in R&D in India. And in recent years, Novartis, AstraZeneca and Roche have all put serious money into R&D in China, the FT notes. Of course, India is seeing plenty of research growth as well — both from foreign firms and from its own drug industry, which has long focused on generic medicines but is now getting into drug development.
诺华最近在印度输了一场专利官司，并且表示它将改变在印度的研发投资计划。最近几年，诺华、阿斯利康以及罗氏均在中国投入重金进行研发，财经时报表示。当然，印度的研发增长也很快——无论是外商还是以往长期依赖仿制药而最近开始进行药物研发的本国企业。

中国注册的临床试验数量超越印度
Jacob Goldstein发布

财经时报报道：根据在美国已注册的全球临床试验数据可知，现在在中国比在印度有更多的临床试验在进行中。

参照clinicaltrials.gov的数据库，对比与印度的260个临床试验，中国现在有274个在进行中。该数据库同时显示在中国有510个已完成和正在进行的临床试验，而印度只有471个。按照财经时报的说法，直到最近印度才在两个方面都有所增长。

这个数字仅是clinicaltrials.gov上列出的40,000个实验中的一小部分。而且可能有些在两个国家都在进行的试验并未列入这个数据库。但是，因为跨国药厂——在clinicaltrials.gov上注册了他们大部分试验——正在对发展中国家的研究及销售越来越感兴趣这个现象是个有趣的发现。

诺华最近在印度输了一场专利官司，并且表示它将改变在印度的研发投资计划。最近几年，诺华、阿斯利康以及罗氏均在中国投入重金进行研发，财经时报表示。当然，印度的研发增长也很快——无论是外商还是以往长期依赖仿制药而最近开始进行药物研发的本国企业。